What is the equity of Immunovant this year?
Immunovant has equity of 617.76 M USD this year.
Immunovant Equity 2024
Immunovant Equity
617.76 M USD
Ticker
IMVT
ISIN
US45258J1025
In 2024, Immunovant's equity was 617.76 M USD, a 31.49% increase from the 469.8 M USD equity in the previous year.
Immunovant Aktienanalyse
What does Immunovant do?
Immunovant ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Immunovant's Equity
Immunovant's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Immunovant's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Immunovant's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Immunovant's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Immunovant’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Immunovant stock
What was the equity of Immunovant compared to the previous year?
The equity of Immunovant has increased/decreased by 31.49% increased compared to the previous year.
What impact does a high equity have on investors of Immunovant?
A high equity is advantageous for investors of Immunovant as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Immunovant?
A low equity can be a risk for investors of Immunovant, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Immunovant affect the company?
An increase in equity of Immunovant can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Immunovant affect the company?
A reduction in equity of Immunovant can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Immunovant?
Some factors that can affect the equity of Immunovant include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Immunovant so important for investors?
The equity of Immunovant is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Immunovant take to change the equity?
To change equity, Immunovant can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Immunovant pay?
Over the past 12 months, Immunovant paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immunovant is expected to pay a dividend of 0 USD.
What is the dividend yield of Immunovant?
The current dividend yield of Immunovant is .
When does Immunovant pay dividends?
Immunovant pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Immunovant?
Immunovant paid dividends every year for the past 0 years.
What is the dividend of Immunovant?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Immunovant located?
Immunovant is assigned to the 'Health' sector.
Wann musste ich die Aktien von Immunovant kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Immunovant from 9/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/24/2024.
When did Immunovant pay the last dividend?
The last dividend was paid out on 9/24/2024.
What was the dividend of Immunovant in the year 2023?
In the year 2023, Immunovant distributed 0 USD as dividends.
In which currency does Immunovant pay out the dividend?
The dividends of Immunovant are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Immunovant
Our stock analysis for Immunovant Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunovant Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.